Literature DB >> 18551573

The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequency.

Kenneth M Peters1, Kim A Killinger, Ibrahim A Ibrahim, Paul S Villalba.   

Abstract

AIMS: Global response assessment (GRA) has been used to evaluate patients' perceptions of treatment effectiveness. However, few studies have scrutinized the relationship between GRAs and objective voiding diary outcomes data. This study explores the relationship between self-reported symptom-specific GRA responses and objective changes in frequency, urgency and pelvic pain in patients with urgency-frequency with or without pelvic pain after implantation of a prosthetic sacral nerve stimulation device.
METHODS: Patients scheduled for a staged procedure were enrolled in a prospective, observational, longitudinal study. Post implantation, patietns were grouped into "responders" or "non-responders" based on their answers to symptom-specific GRAs at three and six months. Treatment responders were defined as those reporting "moderately" or "markedly improved" on a 7-point scale, and all others were considered non-responders. Pre- and post-implant changes in mean 24-hour voiding frequency, voided volume, urgency and pelvic pain scores as recorded on voiding diaries were compared between groups using paired t-test.
RESULTS: At three months, responders demonstrated corresponding statistically significant improvement in voiding frequency (P < 0.001), average voided volume (P = 0.003), urgency (P = 0.022) and pelvic pain (P = 0.039). At six months, responders demonstrated statistically significant improvements in frequency (P = 0.025) and urgency (P = 0.006). None of the symptom changes were statistically significant in treatment non-responders.
CONCLUSIONS: The GRA non-responders groups' perceptions of treatment response agreed with their objective changes in bothersome symptoms and responders' changes agreed with their perception of improvement in the majority of symptoms. Further study is needed to standardize the GRA, and explore its potential for use in clinical practice. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18551573     DOI: 10.1002/nau.20592

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  5 in total

Review 1.  Pelvic pain in urogynaecology. Part I: evaluation, definitions and diagnoses.

Authors:  Tilemachos Kavvadias; Kaven Baessler; Bernhard Schuessler
Journal:  Int Urogynecol J       Date:  2010-07-20       Impact factor: 2.894

Review 2.  Pelvic pain in urogynecology. Part II: treatment options in patients with lower urinary tract symptoms.

Authors:  Tilemachos Kavvadias; Kaven Baessler; Bernhard Schuessler
Journal:  Int Urogynecol J       Date:  2012-01-21       Impact factor: 2.894

Review 3.  Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction.

Authors:  Jennifer Yonaitis Fariello; K Whitmore
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

4.  Retubularization of the ileocystoplasty patch for conversion into an ileal conduit.

Authors:  Peter A Massaro; Jerzy B Gajewski; Greg Bailly
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 5.  Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.

Authors:  David R Staskin; Kenneth M Peters; Scott MacDiarmid; Neal Shore; William C de Groat
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.